Last updated: February 25, 2026
What is the Drug and Its Approved Indications?
NDC 76282-0462 refers to Sovaldi (sofosbuvir), an antiviral medication approved for the treatment of chronic hepatitis C virus (HCV) infection. Approved by the FDA in December 2013, Sovaldi is globally recognized for its high cure rates. It is used alone or in combination with other agents like ledipasvir to treat HCV genotypes 1, 2, 3, 4, 5, and 6.
Market Overview
Key Market Dynamics
- Market Size: The global hepatitis C market was valued at approximately $4.1 billion in 2021.
- Patient Population: Estimated 71 million people infected worldwide as of 2020, with significant treatment demand in the U.S., Europe, and Asia-Pacific.
- Treatment Penetration: Growing use of direct-acting antivirals (DAAs) like sofosbuvir has increased cure rates above 95%, reducing demand for older therapies.
Competitive Landscape
- Major competitors include Gilead (Harvoni, Epclusa), AbbVie (Viekira Pak), and Merck (Zepatier).
- Gilead's products account for over 60% of the market share in the U.S. since 2014.
- Patent expirations are imminent for some formulations, possibly opening generic opportunities by 2025.
Regulatory and Cost Factors
- Optimized treatment durations (8-12 weeks) reduce overall treatment costs.
- Insurance and Medicaid coverage vary widely, influencing pricing strategies.
Price Data and Trends
Historical Pricing
- When launched in 2013, a 12-week course of Sovaldi cost approximately $84,000 in the U.S. (around $1,000 per pill).
- In 2018, the average wholesale price (AWP) for a 12-week course declined by about 60% to approximately $26,400.
Current Pricing (2023)
Based on recent data:
| Price Factors |
Approximate Cost (USD) |
Notes |
| Wholesale Price |
$26,400 |
For a 12-week course |
| Prescriber Discounts |
20% - 30% off WAC |
Varies by payer |
| Negotiated Medicaid / Private Payer Prices |
$20,000 - $25,000 |
After rebates and discounts |
| Patient Out-of-Pocket |
$0 - $5,000 |
Depending on insurance coverage |
Price Projections (Next 3-5 Years)
Factors influencing future prices include patent status, generic entry, and market competition:
| Year |
Expected Price Range (USD) |
Influencing Factors |
| 2024 |
$20,000 - $25,000 |
Near patent expiration; continued payer negotiations |
| 2025 |
$15,000 - $20,000 |
Generic approvals likely; increased market competition |
| 2026 |
$10,000 - $15,000 |
Generic market presence expanding; potential loss of exclusivity |
Potential Price Declines with Generics
- Market entry of generics could reduce prices by 50-70%, aligning with prices seen in markets like India or Egypt, where courses cost under $1,000.
Key Regulatory and Patent Outlook
- Gilead holds key patents until 2024-2025 in the U.S.
- The patent for Sovaldi in the U.S. expired in 2024, opening the door for generic manufacturing.
- WHO prequalification may facilitate global generic approval by 2024-2025.
Market Opportunities and Risks
Opportunities:
- Expanding treatment for underserved populations worldwide.
- Developing combination regimens to improve cure rates and compliance.
Risks:
- Patent challenges and patent cliff effects.
- Pricing pressures from generics and biosimilars.
- Competition from newer agents with shorter regimens or improved side effect profiles.
Key Takeaways
- Sovaldi's 2023 market remains sizable, dominated by high-priced treatments with established payer negotiations.
- Prices have declined significantly since launch, with future declines expected as patents expire and generics enter.
- The next 3-5 years forecast a downward trend in pricing, potentially reaching under $15,000 per course globally by 2026.
- Patent expiration in 2024 opens opportunities for generic manufacturers, likely accelerating price drops.
- Entry of competitors with fixed-dose combinations and shorter regimens could further reshape pricing and market dynamics.
FAQs
1. When will generic versions of Sovaldi become available in the U.S.?
Patents are scheduled to expire in 2024-2025, enabling generic manufacturing and sales.
2. How does the price of Sovaldi compare internationally?
Global prices vary; in high-income markets, treatments can range from $20,000 to $26,400. In lower-income countries with generic access, courses can cost less than $1,000.
3. Are there risks to Gilead’s market share due to generic entry?
Yes, generic entry could significantly reduce Gilead’s pricing power and market share, particularly in countries embracing cost-effective options.
4. What is the impact of new hepatitis C drugs on Sovaldi’s market?
New drugs with shorter treatment durations and improved tolerability could displace Sovaldi, especially as prices decrease.
5. How do payer policies influence the actual treatment costs?
Insurance rebates, discounts, and negotiation strategies can lower out-of-pocket expenses and negotiated prices for payers and patients.
References
- Gilead Sciences. (2022). Product pipeline and label updates. Retrieved from [Gilead website]
- IQVIA. (2022). Global hepatitis C market report.
- U.S. Food and Drug Administration. (2013). Sovaldi approval notice.
- MarketResearch.com. (2022). Hepatitis C therapies market analysis.
- World Health Organization. (2022). Hepatitis C: Global prevalence and treatment access.
